{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:34:53Z","timestamp":1768678493527,"version":"3.49.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.amjmed.2022.01.042","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T03:00:41Z","timestamp":1645498841000},"page":"697-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiplatelet Agents in Acute ST Elevation Myocardial Infarction"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4797-1165","authenticated-orcid":false,"given":"Kris","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Golwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2022.01.042_bib0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2020.05.018","article-title":"Platelets as therapeutic targets to prevent atherosclerosis","volume":"307","author":"Nording","year":"2020","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.042_bib0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4065\/81.1.59","article-title":"Platelets in atherothrombosis","volume":"81","author":"Vorchheimer","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2022.01.042_bib0003","first-page":"990","article-title":"Patient management in the ICU: the PDB System","author":"Salasidis","year":"1991","journal-title":"Proc Annu Symp Comput Appl Med Care"},{"issue":"8607","key":"10.1016\/j.amjmed.2022.01.042_bib0004","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.042_bib0005","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"issue":"9497","key":"10.1016\/j.amjmed.2022.01.042_bib0006","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.amjmed.2022.01.042_bib0007","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.042_bib0008","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jcin.2014.01.160","volume":"7","author":"Udell","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.042_bib0009","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.amjmed.2022.01.042_bib0010","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jacc.2019.03.011","article-title":"Ticagrelor versus clopidogrel in patients With STEMI treated with fibrinolysis: TREAT trial","volume":"73","author":"Berwanger","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.amjmed.2022.01.042_bib0011","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4244\/EIJ-D-20-00268","article-title":"Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial","volume":"16","author":"Hamilos","year":"2021","journal-title":"EuroIntervention"},{"issue":"24","key":"10.1016\/j.amjmed.2022.01.042_bib0012","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIRCULATIONAHA.120.050244","article-title":"Ticagrelor or prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"142","author":"Aytekin","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.042_bib0013","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.107.729558","article-title":"Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy","volume":"117","author":"Berger","year":"2008","journal-title":"Circulation"},{"issue":"9748","key":"10.1016\/j.amjmed.2022.01.042_bib0014","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.042_bib0015","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","article-title":"Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials","volume":"95","author":"Serebruany","year":"2005","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.042_bib0016","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jcin.2012.07.016","volume":"5","author":"Yu","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0017","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCULATIONAHA.114.014992","article-title":"Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study","volume":"132","author":"Xian","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.042_bib0018","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2022.01.042_bib0019","first-page":"25","article-title":"Pharmacokinetics of clopidogrel","volume":"25","author":"Caplain","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.amjmed.2022.01.042_bib0020","first-page":"29","article-title":"Pharmacokinetic profile of 14C-labeled clopidogrel","volume":"25","author":"Lins","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"16","key":"10.1016\/j.amjmed.2022.01.042_bib0021","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.amjmed.2022.01.042_bib0022","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.042_bib0023","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: a review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.amjmed.2022.01.042_bib0024","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.042_bib0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.118.311963","article-title":"Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention","volume":"39","author":"Klein","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.amjmed.2022.01.042_bib0026","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.042_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.042_bib0028","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10928-008-9103-7","article-title":"Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"35","author":"Ernest","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"19","key":"10.1016\/j.amjmed.2022.01.042_bib0029","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2022.01.042_bib0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.amjmed.2022.01.042_bib0031","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.116.024823","article-title":"Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study","volume":"134","author":"Motovska","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.042_bib0032","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.amjmed.2022.01.042_bib0033","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.042_bib0034","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","article-title":"Cangrelor: a review on pharmacology and clinical trial development","volume":"11","author":"Franchi","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.042_bib0035","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1185\/03007995.2014.880050","article-title":"Cangrelor: an emerging therapeutic option for patients with coronary artery disease","volume":"30","author":"Kubica","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0036","doi-asserted-by":"crossref","first-page":"689.e1","DOI":"10.1016\/j.ahj.2005.11.014","article-title":"Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial","volume":"151","author":"Greenbaum","year":"2006","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0037","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","article-title":"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes","volume":"85","author":"Storey","year":"2001","journal-title":"Thromb Haemost"},{"issue":"2 Suppl","key":"10.1016\/j.amjmed.2022.01.042_bib0038","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ahj.2008.06.004","article-title":"Pharmacology of emerging novel platelet inhibitors","volume":"156","author":"Angiolillo","year":"2008","journal-title":"Am Heart J"},{"issue":"24","key":"10.1016\/j.amjmed.2022.01.042_bib0039","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.amjmed.2022.01.042_bib0040","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"issue":"9909","key":"10.1016\/j.amjmed.2022.01.042_bib0041","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.amjmed.2022.01.042_bib0042","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.042_bib0043","first-page":"1445","volume":"6","year":"1997","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.amjmed.2022.01.042_bib0044","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1001\/jama.299.15.joc80026","article-title":"Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial","volume":"299","author":"Valgimigli","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.042_bib0045","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.95.4.846","article-title":"Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb\/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators","volume":"95","author":"Ohman","year":"1997","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.042_bib0046","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.acvd.2010.04.005","article-title":"Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study","volume":"103","author":"El Khoury","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.042_bib0047","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ahj.2006.06.003","article-title":"Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial","volume":"152","author":"Gibson","year":"2006","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.042_bib0048","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2009.10.093","article-title":"Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)","volume":"56","author":"Akerblom","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.amjmed.2022.01.042_bib0049","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1161\/CIRCULATIONAHA.110.002741","volume":"122","author":"Gu","year":"2010","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.amjmed.2022.01.042_bib0050","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.amjmed.2022.01.042_bib0051","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0052","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"5","author":"Grimfj\u00e4rd","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.042_bib0053","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI119307","article-title":"Platelet GPIIb\/IIIa antagonists: the first anti-integrin receptor therapeutics","volume":"99","author":"Coller","year":"1997","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.042_bib0054","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2008-06-077891","article-title":"The GPIIb\/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend","volume":"112","author":"Coller","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCINTERVENTIONS.108.847996","article-title":"A comparison of abciximab and small-molecule glycoprotein IIb\/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials","volume":"2","author":"Gurm","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0056","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","article-title":"Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high risk patients undergoing coronary angioplasty","volume":"27","author":"Kereiakes","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.amjmed.2022.01.042_bib0057","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9149(99)80345-2","article-title":"Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb\/IIIa inhibitor during percutaneous coronary intervention","volume":"76","author":"Harrington","year":"1995","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.042_bib0058","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0735-1097(01)01165-2","article-title":"Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting","volume":"37","author":"Neumann","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"9510","key":"10.1016\/j.amjmed.2022.01.042_bib0059","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(06)68148-8","article-title":"Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials","volume":"367","author":"Keeley","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0060","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.292.3.362","article-title":"Early vs late administration of glycoprotein IIb\/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis","volume":"292","author":"Montalescot","year":"2004","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.amjmed.2022.01.042_bib0061","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jama.293.14.1759","article-title":"Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials","volume":"293","author":"De Luca","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.042_bib0062","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/eurheartj\/ehl472","article-title":"Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up","volume":"28","author":"Montalescot","year":"2007","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.amjmed.2022.01.042_bib0063","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jacc.2006.12.036","article-title":"Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial)","volume":"49","author":"Maioli","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"9638","key":"10.1016\/j.amjmed.2022.01.042_bib0064","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","article-title":"Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial","volume":"372","author":"Van't Hof","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.042_bib0065","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1016\/j.ahj.2003.07.025","article-title":"Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial","volume":"147","author":"Ellis","year":"2004","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.042_bib0066","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcin.2009.07.009","article-title":"1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial","volume":"2","author":"Ellis","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"issue":"22","key":"10.1016\/j.amjmed.2022.01.042_bib0067","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","article-title":"Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome","volume":"55","author":"ten Berg","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.042_bib0068","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","article-title":"Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators","volume":"98","author":"Brener","year":"1998","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.amjmed.2022.01.042_bib0069","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.amjmed.2022.01.042_bib0070","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/eurheartj\/ehi293","article-title":"Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial","volume":"26","author":"Zeymer","year":"2005","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.042_bib0071","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjcard.2011.10.016","article-title":"Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"109","author":"Shimada","year":"2012","journal-title":"Am J Cardiol"},{"issue":"17","key":"10.1016\/j.amjmed.2022.01.042_bib0072","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1001\/jama.2012.421","article-title":"Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial","volume":"307","author":"Stone","year":"2012","journal-title":"JAMA"},{"issue":"9819","key":"10.1016\/j.amjmed.2022.01.042_bib0073","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(11)61872-2","article-title":"Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial","volume":"379","author":"Thiele","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.042_bib0074","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.amjcard.2011.11.053","article-title":"Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb\/IIIa inhibitors in patients with ST-elevation myocardial infarction","volume":"109","author":"Wang","year":"2012","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.042_bib0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/157340308786349480","article-title":"The optimal route of administration of the glycoprotein IIb\/IIIa receptor antagonist abciximab during percutaneous coronary intervention; intravenous versus intracoronary","volume":"4","author":"Iversen","year":"2008","journal-title":"Curr Cardiol Rev"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.042_bib0076","first-page":"186","article-title":"Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention","volume":"62","author":"Bellandi","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.042_bib0077","first-page":"31","article-title":"Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting","volume":"61","author":"Kakkar","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.042_bib0078","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijcard.2004.11.037","article-title":"Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI","volume":"105","author":"Romagnoli","year":"2005","journal-title":"Int J Cardiol"},{"issue":"14","key":"10.1016\/j.amjmed.2022.01.042_bib0079","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/01.CIR.0000066852.98038.D1","article-title":"Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty","volume":"107","author":"W\u00f6hrle","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.amjmed.2022.01.042_bib0080","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.amjcard.2010.01.006","volume":"105","author":"Bertrand","year":"2010","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.amjmed.2022.01.042_bib0081","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","article-title":"Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial","volume":"119","author":"Mehilli","year":"2009","journal-title":"Circulation"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322001267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322001267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:27:58Z","timestamp":1757582878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0002934322001267"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.042","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet Agents in Acute ST Elevation Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}